文献速递肝病

基于血液的肝脏分泌组特征可预测肝硬化长期失代偿风险

A Blood-Based Prognostic Liver Secretome Signature Predicts Long-term Risk of Hepatic Decompensation in Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-03-13

肝硬化失代偿预测是未满足的临床需求。该研究评估了一种基于血液的预后肝脏分泌组特征对肝硬化患者长期肝功能失代偿风险的预测价值,并与ALBI-FIB4等临床评分进行比较,指出外部验证显示现有评分预测能力欠佳。

要点

  • 肝硬化患者中位生存期代偿期约12年,失代偿期仅2年。
  • 准确预测肝功能失代偿有助于识别需密切监测和及时干预的患者。
  • 现有临床评分如ALBI-FIB4外部验证预测能力欠佳,存在改进空间。

核心结论

  • 基于血液的肝脏分泌组特征有望预测肝硬化患者长期肝功能失代偿风险。

研究设计与样本

  • 研究设计与样本量原文未报告。

主要发现

  • 代偿期肝硬化中位生存期约12年,失代偿期仅2年。
  • ALBI-FIB4等临床评分外部验证常显示预测能力欠佳。

关键数值与推荐

  • ALBI-FIB4评分被提出用于预测长期肝功能失代偿风险,但外部验证预测能力欠佳。

临床怎么用

  • 该血液分泌组特征可用于识别能从密切监测和及时干预中获益的肝硬化患者。
  • 风险分层有助于筛选适合参加预防肝功能失代偿试验的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cirrhosis is the terminal stage of progressive liver fibrosis, affecting 1%-2% of the global population and accounting for 1.3 million deaths annually.1,2 Median survival for persons with compensated cirrhosis is approximately 12 years, compared with only 2 years for those with hepatic decompensation. Accurate prediction of hepatic decompensation is an unmet need to enable identification of patients with cirrhosis who could benefit from close monitoring and timely medical interventions. Besides, risk stratification of patients with cirrhosis could help inform patient selection for trials evaluating therapies to prevent hepatic decompensation. Although various clinical scores, such as the albumin-bilirubin (ALBI) and fibrosis-4 (FIB-4) indices (ALBI-FIB4 score) have been proposed to predict long-term risk of hepatic decompensation,3 external validation has often shown suboptimal prognostic capability and revealed room for improvement.4.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Fujiwara N, Fobar AJ, Raman I, et al. A Blood-Based Prognostic Liver Secretome Signature Predicts Long-term Risk of Hepatic Decompensation in Cirrhosis. Clin Gastroenterol Hepatol. 2021. PMID: 33727162. doi:10.1016/j.cgh.2021.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。